Surface-modified PLGA nanoparticles with PEG/LA-Chitosan for targeted delivery of arsenic trioxide for liver cancer treatment: Inhibition effects enhanced and Side effects reduced

In this study, polyethylene glycol (PEG) and lactobionic acid (LA) modified chitosan (PLC) was synthesized and was used to coat poly(lactide-co-glycolide) (PLGA) nanoparticles for encapsulation and targeted release of As2O3 in liver cancer treatment. The As2O3-loaded PLGA/PLC nanoparticles (As2O3-PLGA/PLC NPs) were fabricated through double emulsion-solvent evaporation method and were optimized by orthogonal tests. As2O3-PLGA/PLC NPs presented suitable physical stability, positive charge, high encapsulation efficiency and drug loading, and good biocompatibility. As expected, the NPs can quickly release enough dose of As2O3 in a short time and then sustain the drug concentration. The As2O3-PLGA/PLC NPs showed effective inhibition of SMMC-7721 cells while having lower cytotoxicity against normal human liver cells (LO2 cells). Furthermore, In vivo study showed that the NPs did not present toxic effects on kidney and liver, but showed relatively high growth inhibition effect on liver tumor. Therefore, this PLGA/PLC NPs could be an effective and safe drug delivery system for liver cancer chemotherapy.Graphical abstract
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research

Related Links:

Authors: Sun W, Shen NM, Fu SL Abstract Cervical cancer (CC) develops, after human papillomavirus (HPV), an infection transmitted through sexual contact. Worldwide estimates are around>500,000 CC diagnoses and>300,000 related deaths annually, and CC remains the second most devastating type of cancers in women after breast cancer. Although the vaccine against HPV has reduced the incidence of infection and the treatment efficacy of the early-stage diagnoses has improved, many challenges remain in terms of treatment efficacy, during the late-stage and prevention of chemotherapy resistance development. Thus, new ...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Authors: Kunitomi A, Hasegawa Y, Lmamura J, Yokomaku Y, Tokunaga T, Miyata Y, Iida H, Nagai H Abstract Acute promyelocytic leukemia (APL) in human immunodeficiency virus (HIV)-infected individuals is very rare. There is currently no consensus regarding the use of anti-cancer drugs with highly active anti-retroviral therapy (ART) in these patients due to their small number. We herein report two cases of APL with HIV-infected patients. Both cases received all-trans-retinoic acid-containing chemotherapies and achieved complete remission. ART was continued throughout the treatment course. The clinical course of these c...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Following publication of the original article [1], the authors reported that the incorrect Fig. 2A was published in the article. The recovery times required to achieve a normal neutrophil count was omitted. Th...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Correction Source Type: research
We present a case of a 19-month infant who was taken to the Emergency Department due to fever and a gingival lesion that did not respond to antibiotic treatment. An ultrasound study was requested to assess the presence of an abscess. However, a lesion was identified and after performing a biopsy, pathologist found it was a myeloid sarcoma. The patient was diagnosed with AML and chemotherapy treatment was started. After three cycles of treatment, the patient is currently free of disease.
Source: Revista Espanola de Cirugia Oral y Maxilofacial - Category: ENT & OMF Source Type: research
We present a case of a 19-month infant who was taken to the Emergency Department due to fever and a gingival lesion that did not respond to antibiotic treatment. An ultrasound study was requested to assess the presence of an abscess. However, a lesion was identified and after performing a biopsy, pathologist found it was a myeloid sarcoma. The patient was diagnosed with AML and chemotherapy treatment was started. After three cycles of treatment, the patient is currently free of disease.
Source: Revista Espanola de Cirugia Oral y Maxilofacial - Category: ENT & OMF Source Type: research
ConclusionThe use of pediatric-inspired protocol for high risk AYA ALL was effective and well tolerated with improvement in OS and DFS compared to historical data using adult protocols in such population
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Sarah Cannon Research Institute in Nashville, Tennessee, and MD Anderson Cancer Center in Houston have opened a much-anticipated clinical trial involving a novel T-cell therapy for patients with mesothelioma. The two institutions are establishing dosage levels and measuring efficacy of TC-210, a type of immunotherapy that targets mesothelin, a cell surface protein highly expressed in several cancers. The study also is open to patients with certain types of bile duct, ovarian and non-small cell lung cancer. Participation is based upon individual levels of mesothelin expression. Researchers at the two centers are hoping to ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Publication date: Available online 15 May 2019Source: Mutation Research/Genetic Toxicology and Environmental MutagenesisAuthor(s): P. Gollapudi, V.S. Bhat, D.A. EastmondAbstractTopoisomerase II (topo II) inhibitors are commonly used as chemotherapy to treat multiple types of cancer, though their use is also associated with the development of therapy related acute leukemias. While the chromosome-damaging effects of etoposide, a topo II poison, have been proposed to act through a threshold mechanism, little is known about the chromosome damaging effects and dose responses for the catalytic inhibitors of the enzyme. The curre...
Source: Mutation Research Genetic Toxicology and Environmental Mutagenesis - Category: Genetics & Stem Cells Source Type: research
In this study, we examined whether GCs affected the sensitivities to vincristine (VCR)/doxorubicin (DOX) and the expression of drug transporters in GC-resistant cells. The dexamethasone (DEX)/prednisolone (PSL)-resistant lymphoid and non-lymphoid cell lines Raji and HL60 were cultured with DEX for 7 days and then treated with VCR or DOX for 3 days. Seven days of DEX treatment increased the IC50s of both VCR and DOX in Raji cells but not in HL60 cells. The mRNA and protein expression levels of organic cation/carnitine transporter (OCTN) 2, one of the drug uptake transporters expressed in both cell lines, were decr...
Source: Molecular and Cellular Biochemistry - Category: Biochemistry Authors: Tags: Mol Cell Biochem Source Type: research
ConclusionCytokines explain a relatively small amount of CRF and QOL scores in patients with AML and effects differ by age group. For cytokine-targeted therapies to improve either outcome, multiple cytokines may need to be substantially altered and therapeutic targets may vary with age.
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
More News: Biochemistry | Cancer | Cancer & Oncology | Chemotherapy | Leukemia | Liver | Nanotechnology | Polyethylene Glycol | Study | Toxicology | Urology & Nephrology